Curaleaf said this morning it intends to launch a takeover bid for Aurora Cannabis, and the operative word is intends. The release carries its own warning label: "No formal take-over bid has been commenced and there is no assurance the proposed offer will ultimately be made" [1]. Everything that follows, every premium and synergy figure now moving both stock prices, is the bidder's arithmetic, published before any offer document exists.
The consideration decomposes cleanly. Each Aurora share would receive 0.3463 Curaleaf subordinate voting shares plus US$0.75 in cash, which Curaleaf values at US$4.00 [1]. Work backward and that implies a Curaleaf share price near US$9.38, since US$4.00 minus the US$0.75 cash leaves US$3.25 of stock, and US$3.25 divided by 0.3463 is US$9.38. The stock portion floats: if Curaleaf's shares rise before the bid closes, the package is worth more, up to a hard ceiling of US$5.00 per Aurora share, enforced by shrinking the share ratio based on Curaleaf's 20-day VWAP [1].
The ceiling has a location, and it is close. The package hits US$5.00 when the stock component reaches US$4.25, which at the 0.3463 ratio means Curaleaf trading near US$12.27. From the implied US$9.38, that is a rally of about 31 percent. An Aurora holder accepting stock participates in Curaleaf's upside for the first 31 percent and not a dollar after; past the cap, the ratio adjustment claws the excess back to the bidder [1]. The release describes no mirror-image mechanism on the way down. As published, the structure has a ceiling for the seller and no stated floor, which means the US$4.00 headline value is a snapshot, not a guarantee.
The premium comes framed two ways, and the spread between the framings is the tell. Against Aurora's 30-day volume-weighted average price of US$2.75, the US$4.00 offer is a 45 percent premium; that division checks, 4.00 over 2.75 is 1.45 [1]. The release's alternative figure is 110 percent, computed by excluding Aurora's balance-sheet cash from both sides [1]. The release does not print the cash figure that calculation uses, but the algebra recovers it: for a 45 percent premium to become 110 percent, Aurora must carry about US$1.61 per share in cash, leaving an ex-cash business the market prices at US$1.14 against an ex-cash offer of US$2.39. The cross-check confirms it: at the US$5.00 cap the release claims an 82 percent premium, which is 5.00 over 2.75, and 197 percent excluding cash, and the same US$1.61 of cash per share reproduces that 197 almost exactly [1]. The ex-cash framing is internally consistent. What it assumes is worth saying plainly: it treats Aurora's cash as a pass-through and measures the premium only on the shrunken remainder, which is precisely how a 45 becomes a 110 without the offer growing by a cent.
The scale claims round out the release. Curaleaf projects at least US$40 million in annual cost synergies, pro forma last-twelve-months revenue above US$1.5 billion, nearly US$350 million in pro forma adjusted EBITDA, and a combined market capitalization approaching US$3.0 billion [1]. Each figure is the bidder's own estimate, published in the bidder's own announcement, ahead of any binding commitment.
What exists as of this morning is a press release with moving parts: a floating package worth US$4.00 at announcement, a ceiling 25 percent above it, no stated floor beneath it, and a sentence confirming the bid itself may never arrive [1]. The numbers to watch from here are Curaleaf's share price against the US$12.27 cap trigger, and whether an actual offer document follows the intention.
